These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15276594)

  • 21. Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial.
    Han Q; Liu Z; Kang W; Li H; Zhang L; Zhang N
    Dig Dis Sci; 2008 Aug; 53(8):2238-45. PubMed ID: 18080763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.
    Jin R; Cai L; Tan M; McHutchison JG; Dowling TC; Howell CD
    Am J Gastroenterol; 2012 Nov; 107(11):1675-83. PubMed ID: 23090351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study.
    Bjøro K; Bell H; Hellum KB; Skaug K; Raknerud N; Sandvei P; Døskeland B; Maeland A; Lund-Tønnesen S; Myrvang B
    Scand J Gastroenterol; 2002 Feb; 37(2):226-32. PubMed ID: 11843062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.
    Jeffers LJ; Cassidy W; Howell CD; Hu S; Reddy KR
    Hepatology; 2004 Jun; 39(6):1702-8. PubMed ID: 15185312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.
    Thuluvath PJ; Maheshwari A; Mehdi J; Fairbanks KD; Wu LL; Gelrud LG; Ryan MJ; Anania FA; Lobis IF; Black M
    Gut; 2004 Jan; 53(1):130-5. PubMed ID: 14684587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.
    Di Marco V; Covolo L; Calvaruso V; Levrero M; Puoti M; Suter F; Gaeta GB; Ferrari C; Raimondo G; Fattovich G; Santantonio T; Alberti A; Bruno R; Mussini C; Mondelli M; Donato F; Craxì A;
    J Viral Hepat; 2013 Nov; 20(11):790-800. PubMed ID: 24168258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.
    Conjeevaram HS; Fried MW; Jeffers LJ; Terrault NA; Wiley-Lucas TE; Afdhal N; Brown RS; Belle SH; Hoofnagle JH; Kleiner DE; Howell CD;
    Gastroenterology; 2006 Aug; 131(2):470-7. PubMed ID: 16890601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.
    Shi KQ; Liu WY; Lin XF; Fan YC; Chen YP; Zheng MH
    Gene; 2012 Oct; 507(1):27-35. PubMed ID: 22842190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection.
    Hoofnagle JH; Wahed AS; Brown RS; Howell CD; Belle SH;
    J Infect Dis; 2009 Apr; 199(8):1112-20. PubMed ID: 19284286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.
    Flamm SL; Muir AJ; Fried MW; Reddy KR; Nelson DR; Bzowej NH; Sullivan JC; Bengtsson L; DeMasi R; Wright CI; Kieffer TL; George S; Adda N; Dusheiko GM
    J Clin Gastroenterol; 2015 Apr; 49(4):336-44. PubMed ID: 24828357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
    Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
    Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C.
    Brennan BJ; Morcos PN; Wang K; Blotner SD; Morrison R; Hagedorn CH; Marbury TC; Sulkowski M; Grippo JF
    Aliment Pharmacol Ther; 2012 May; 35(10):1209-20. PubMed ID: 22469033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
    Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
    Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6.
    Nguyen NH; VuTien P; Garcia RT; Trinh H; Nguyen H; Nguyen K; Levitt B; Nguyen MH
    J Viral Hepat; 2010 Oct; 17(10):691-7. PubMed ID: 20002562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.
    Shiffman ML
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S13-6. PubMed ID: 15468612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic hepatitis C treatment patterns in African American patients: an update.
    Daniel S
    Am J Gastroenterol; 2005 Mar; 100(3):716-22. PubMed ID: 15743373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.